Vivesto presents new Paccal Vet survival and safety data from dog hemangiosarcoma pilot study at VCS 2026
Bitget2026/09/24 06:03- Vivesto flagged newly reported topline results from two Paccal Vet studies for presentation at the Veterinary Cancer Society conference on Sept. 24.
- Dog pilot study in splenic hemangiosarcoma showed supportive survival and safety outcomes, reinforcing the case to move into a pivotal trial.
- Cat dose-escalation study indicated tolerability with early signs of single-agent anti-tumor activity; final results are expected in Q4 2026.
- Data were previously presented as topline results in September 2026; the conference posters provide an external forum for scientific review.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Circle issues 500 million USDC on the Solana network

Cardano vs Solana: Analysts and ADA Holders Clash Over Adoption

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share
Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

